Pilot Study of Pancreatic Cancer Screening

Status Recruiting

Clinical Trial Summary

This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the event rate of abnormal magnetic resonance imaging (MRI) findings in screened study participants. SECONDARY OBJECTIVES: I. To determine the rates of high-grade pancreatic neoplasia precursors (intraductal papillary mucinous neoplasm (IPMN)-high-grade dysplasia (HGD)) and pancreatic intraepithelial neoplasia-3 [PanIN-3]) and pancreatic ductal adenocarcinoma (PDAC) among all study participants. II. To understand rates of procedures (biopsies and surgeries) among all study participants. EXPLORATORY OBJECTIVES: I. To create a biorepository of all participants through the collection of saliva, blood, and tissue, combined with imaging findings and robust clinical annotation of patient health behaviors in all study participants. II. To explore knowledge, attitudes, and anxiety related to pancreatic cancer screening at annual intervals in all study participants. OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I: Participants may opt to undergo MRI/ magnetic resonance cholangiopancreatography (MRCP) annually for 10 years or complete questionnaires over 10 minutes and undergo blood, saliva and tissue sample collection. GROUP II: Participants undergo MRI/MRCP screening annually for 10 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05058846
Study type	Observational
Source	University of California, San Francisco
Contact	Phu Lam
Phone	(415) 353-8337
Email	Phu.Lam@ucsf.edu
Status	Recruiting
Phase
Start date	January 20, 2022
Completion date	January 31, 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05237193` - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting	`NCT04602026` - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer	N/A
Recruiting	`NCT05613465` - Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo	N/A
Completed	`NCT03645148` - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer	Phase 1
Recruiting	`NCT02587689` - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor	Phase 1/Phase 2
Active, not recruiting	`NCT02676349` - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)	Phase 2
Active, not recruiting	`NCT03267524` - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Recruiting	`NCT05642962` - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/Phase 2
Active, not recruiting	`NCT03164486` - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide	Early Phase 1
Active, not recruiting	`NCT02009449` - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors	Phase 1
Terminated	`NCT03137706` - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Not yet recruiting	`NCT06080854` - AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer	Phase 2
Completed	`NCT03962478` - Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction	N/A
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Terminated	`NCT00907166` - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients	Phase 1/Phase 2
Not yet recruiting	`NCT06271291` - Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Active, not recruiting	`NCT03752398` - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)	Phase 1
Completed	`NCT03949933` - Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer	N/A